



Understanding  
Clinical Trial Design:  
*A Tutorial for  
Research Advocates*

# Understanding Clinical Trial Design: *A Tutorial for Research Advocates*

Authored by Jane Perlmutter, PhD  
for Research Advocacy Network's Advocate Institute

## Table of Contents

<b>I. Introduction</b> . . . . .	1
About the Tutorial . . . . .	1
Trade-offs in Designing Clinical Trials . . . . .	2
<b>II. Questions to Ask about Clinical Trials</b> . . . . .	3
What Research Questions Are Being Addressed In The Trial, And How Important Are They? . . . . .	4
Why Should The Trial Be Conducted—i.e., Does The Scientific Rationale Adequately Support the Research Questions? . . . . .	5
Who Will Be Involved In The Trial And How Likely Are They To Embrace It? . . . . .	5
How Well Designed Is The Trial To Answer The Questions It Addresses? . . . . .	6
PICO: Patient Issues . . . . .	6
PICO: Intervention Issues . . . . .	7
PICO: Comparison Issues . . . . .	8
PICO: Outcome Issues . . . . .	8
<b>III. Introduction to Clinical Trial Design</b> . . . . .	11
The Scientific Method Applied to Medicine . . . . .	11
Randomized Controlled Trials . . . . .	14
Hypothesis Testing and Statistical Inference . . . . .	16
<b>IV. Innovations in Trial Design</b> . . . . .	23
Introduction to Bayesian Concepts . . . . .	23
Introduction to Adaptive Designs . . . . .	27
Patient Allocation Adaptive Design . . . . .	29
Patient Preference Design . . . . .	31
Patient Enrichment Strategy . . . . .	32
Randomized Discontinuation Design . . . . .	32
Summary: Adaptive Design . . . . .	34
<b>V. Conclusions</b> . . . . .	35
<b>VI. Acknowledgements</b> . . . . .	36
<b>VII. Recommended Reading</b> . . . . .	37
Introductory Statistics . . . . .	37
History of Statistics . . . . .	37
Drug Development . . . . .	37
Bayesian Statistics . . . . .	37
Adaptive Designs . . . . .	37
<b>VIII. Glossary</b> . . . . .	38
Glossary Sources . . . . .	52

## List of Figures

1 Design of Clinical Trials: Striking a Balance . . . . .	2
2 Thinking About Clinical Trials . . . . .	4
3 Francis Bacon . . . . .	11
4 The Scientific Method . . . . .	12
5 Randomized Clinical Trials: The “Gold Standard” . . . . .	14
6 Ronald Fisher . . . . .	16
7 Introduction of Randomized Controlled Trials . . . . .	17
8 Statistical Inference in Hypothesis Testing . . . . .	18
9 Errors in Hypothesis Testing . . . . .	19
10 Thomas Bayes . . . . .	23
11 Paradigm Shift . . . . .	23
12 Baye’s Theorem . . . . .	24
13 Frequentist versus Bayesian Approaches . . . . .	26
14 Patient Allocation Adaptive Design . . . . .	30
15 Patient Preference Design . . . . .	31
16 Randomized Discontinuation Design . . . . .	33

## List of Examples

Concept Development Example . . . . .	12
Experimental Design (PICO) Example . . . . .	13
Confounding Example . . . . .	14
Blinding Example . . . . .	15
Stratification Example . . . . .	16
Null Hypothesis Example . . . . .	17
Statistical Inference Example . . . . .	18
Judicial Inference Example . . . . .	21
Bayesian Sports Example . . . . .	25
Bayesian Diagnostic Example . . . . .	25
Bayesian Clinical Trial Example . . . . .	26
Adaptation Method Example . . . . .	28
Adaptation Rule Examples . . . . .	28
Patient Allocation Adaptive Design Example . . . . .	29
Patient Preference Design Example . . . . .	31
Patient Enrichment Example . . . . .	32
Randomized Discontinuation Design Example . . . . .	33

# I. Introduction

## About the Tutorial

The purpose of this tutorial is to provide a strategy that *research advocates* can use to constructively contribute to planning *clinical trials*. It should also assist them to critically assess already designed trials they may be asked to critique (e.g., in grant proposals), as well as to evaluate completed trials (e.g., in journal articles).

The presentation is based on three assumptions about the role of *research advocates*. First, *research advocates* have a unique and important contribution to make to clinical research. This is because their focus is primarily on treating patients, rather than on advancing science or careers. Also, their perspective is holistic rather than disease focused. Further *research advocates'* energy, sense of urgency and varied experiences outside of research add much value. Second, the most constructive approach *research advocates* can use to impact research is to raise questions. Raising questions is both less threatening to scientists and less daunting to advocates than providing suggestions. Third, effective research advocates need not be experts in *experimental design*, *statistics*, or science. Nevertheless, the more familiar they become with these areas, and the more comfortable they become with the language and style of scientific discourse, the more effective they will be in influencing the course of research.

This tutorial follows from these assumptions. Generic questions that *advocates* can ask about virtually any *clinical trial* are presented first. Limited knowledge of *clinical trials* is required to tackle this section, but by its conclusion readers who do not already have a conceptual framework for thinking about *clinical trials* should have obtained one (c.f., Figure 2). Additionally, a glossary that contains *italicized* terms is provided to support readers of varying backgrounds.


For many readers, the section devoted to questions will be sufficient. However, because *advocates'* input is enhanced by their understanding of the underlying science, additional background on *clinical trial* design will also be provided. First the underlying logic of traditional *clinical trials* is described. This discussion focuses on *randomized controlled trials* which are the basis of approval of most new medical *treatments*. It will include an introduction to *hypothesis testing* and basic *statistical* concepts. While not essential to *research advocates*, familiarity with these concepts will help them understand and engage in discussions of *clinical trials*. Next, a brief introduction to innovative approaches to *clinical trial* design will be presented. This will include discussion of *Bayesian* approaches and *adaptive designs*.

## Trade-offs in Designing Clinical Trials

*Research advocates* are increasingly playing an important role in designing *clinical trials* that are patient focused and likely to lead to important changes in clinical practice. We want to be sure that *clinical trials* are designed in a way that will lead to unequivocal results (i.e., are effective at answering research questions). However, we also want to be sure that trials can be completed as rapidly and inexpensively as possible (i.e., efficiently use resources), and that the patients who volunteer to be in trials get the best possible *treatment* (i.e., the trials achieve the highest ethical standards). These goals are often at cross purposes; thus, *clinical trial* designs generally represent a compromise. As shown in Figure 1 (page 2), in

In addition to these trade-offs, trial designs must balance the priorities of many stakeholders, including trial sponsors, funders, regulators, principle investigators, research collaborators, and community healthcare providers.

**Figure 1. Design of Clinical Trials: Striking a Balance**



Researchers are most concerned with the soundness of the science. They are trained to be methodical, and because their work builds upon previous trials, they place a premium on maintaining a strong scientific foundation. To protect against making errors, their trial designs typically require a large number of patients and a long time to reach conclusions. They also cost a great deal of money. Even so, for a variety of reasons many trials never lead to definitive conclusions. For example, trials often close prematurely because of slow accrual or loss of funding. Also, unanticipated problems with the selection of patients, procedures used during the trial, or very small differences between the *interventions* being compared can result in inconclusive trials.

Like researchers, informed *research advocates* should place a high premium on sound science. However, we also need to keep the urgency to rapidly find new *treatments* front and center. There is good reason to believe that innovative approaches to designing *clinical trials* can often reduce the time and money needed to successfully complete them. Such approaches can also improve the *treatment* patients receive on trials, while at the same time maintaining the highest standards of sound science. By asking the right questions, *research advocates* can encourage researchers to be more innovative in their trial designs.

## II. Questions to Ask About Clinical Trials

This section should assist *research advocates* to formulate useful questions to raise about *clinical trial* design. The questions are generic, but not exhaustive. Asking generic questions is often possible and even preferable to raising specific suggestions, especially for *research advocates* whose primary role is to maintain focus on all aspects of patients' lives. Most of the questions require limited background in *clinical trial* design, whereas the underpinnings for the more challenging questions are provided in the remainder of this tutorial.

Perhaps the most important questions to ask are:

*Will the study design thoroughly address the primary question of the trial?*

*What alternative trials designs were considered and why was this one selected?*

Having researchers articulate the answer to this question has a number of benefits.

- It focuses attention on the primary question the study is supposed to answer.
- It ensures that researchers have seriously thought about the strengths and weaknesses of their chosen trial design relative to alternatives, and requires them to clarify and weigh the alternatives.
- If the question is asked in the presence of other researchers, it opens up discussion among knowledgeable people who may have different opinions on the topic.
- It helps *research advocates* better understand trial design.
- It helps the *research advocate* explain and justify the trial to potential participants and supporters of the trials.
- It gives researchers practice at discussing *clinical trials* in ways that will be understandable to patients they will recruit for their trials.

In the remainder of this section four generic questions will be developed which will help organize thinking about *clinical trials*. As shown in Figure 2, they relate to the what, why, how, and who of *clinical trials*. The questions are:

- 1) What research questions are being addressed in the trial, and how important are they?
- 2) Why should the trial be conducted—i.e., does the scientific rationale adequately support the research questions?
- 3) Who will support the trial and how likely are they to embrace it?
- 4) How well designed is the trial to answer the questions it addresses?

Figure 2 (page 4) also indicates the key components underlying each of these questions, as well as the section of a grant proposal, trial *protocol* or journal article in which information relevant to each question can typically be found.

**Figure 2. Thinking about Clinical Trials**

Topic	Over-Arching Question	Key Components	Where Addressed
What?	What research questions are being addressed in the trial, and how important are they?	<ul style="list-style-type: none"> <li>• Historical Context</li> <li>• Clinical Importance</li> </ul>	Aims
Why?	Why should the trial be conducted — i.e., does the scientific rationale adequately support the research question?	<ul style="list-style-type: none"> <li>• Pre-trial Data</li> <li>• Biologic Processes</li> </ul>	Background
Who?	Who will support the trial and how likely are they to embrace it?	<ul style="list-style-type: none"> <li>• Physician's Perspective</li> <li>• Clinical Sites</li> <li>• Patient Accrual</li> <li>• Patient Retention</li> </ul>	Appendix
How?	How well designed is the trial to answer the research questions it addresses?	<ul style="list-style-type: none"> <li>• Patients</li> <li>• Intervention</li> <li>• Comparison or Control</li> <li>• Outcome</li> </ul>	Method

Raising some of the more specific questions presented in the remainder of this section will allow *research advocates* to engage in discussions with researchers to ensure that trial designs have adequately addressed issues that are important to patients.

### What Research Questions Are Being Addressed In The Trial, And How Important Are They?

*Research advocates* are constantly aware of the limited number of patient volunteers and other resources that are available for *clinical trials*, as well as the urgency to make rapid progress in discovering better *treatments*. Thus, in assessing any trial, we should try to determine its potential to change clinical practice, compared to alternative trials that might be conducted.

In the best case scenario, what information will be gained from this trial?

- How likely is this trial to lead to changes in clinical practice?
- Will this knowledge still be relevant by the time the trial is likely to be completed?
- How many future patients are likely to be impacted by the results of this trial?

What are the *opportunity costs* associated with this trial?

- What alternative trials are competing for patients and other resources that will be involved in this trial?
- Are there alternative, less costly or less time consuming ways to obtain the same knowledge?

How useful will this trial be to future researchers?

- Will patients be followed after the trial with the goal of collecting evidence about *secondary endpoints*, and long-term *side effects* (e.g., secondary cancers, cognitive deficits, survivorship issues)?
- Will patients' bio-specimens (e.g., blood, tumor tissue) be banked so that it can be used to shed light on *biomarkers* that may be of interest to future researchers?
- Are the processes by which bio-specimens are collected, handled and stored adequately specified to ensure that they will be useful to future researchers?

## Why Should The Trial Be Conducted—i.e., Does The Scientific Rationale Adequately Support The Research Questions?

A key component of success of a *clinical trial* is the strength of the underlying science. Thus, it is important to raise questions about both pre-trial data and underlying biological processes. Researchers should be willing and able to answer these questions in ways that are understandable to *research advocates*, not to mention the public that often funds their work and the patients who participate in their trials. Although *research advocates* will not always be in a strong position to evaluate all aspects of the answers they receive to these questions, they will generally be able to differentiate between potential trials that are scientifically well-grounded, versus those with limited scientific basis or muddled logic.

How strong are pre-trial data?

- Has this *intervention* already been proven in other patient *populations* (e.g., for cancers in other organ sites or stages)? What makes the researchers believe it will also be effective in this trial?
- Is there strong evidence that the *intervention* works in an appropriate animal model? What are the strengths and weaknesses of the animal model?
- Is there strong evidence that the *intervention* works in an appropriate *in vitro* model? What are the strengths and weaknesses of the *in vitro* model?

How strong is the underlying biology?

- Is the *experimental intervention* targeted at a well established biological mechanism?
- How strong is the evidence that this mechanism is important to the disease process?
- How strong is the evidence that the *experimental intervention* will be effective in modifying this mechanism?

## Who Will Be Involved In The Trial And How Likely Are They To Embrace It?

Even if there is good scientific reason to believe that a trial will be scientifically successful, unless patients can be recruited and retained, the trial will not succeed. Indeed, many trials are terminated early because they cannot recruit enough patients. In such cases all resources that went into planning and partially completing the trial are essentially wasted. Thus, it is important to assess the likelihood that the trial can be successfully completed.

How attractive is the trial *protocol* from the point of view of physicians who are likely to recruit patients?

- Will it be easy to provide the *intervention*?
- Will it be easy to collect the required data?
- Is there adequate compensation?
- Are other effective *interventions* available for eligible patients?
- Are other interesting trials available for eligible patients?

What sites are likely to open this trial?

- Who is sponsoring this trial and how strongly will they “market” it?
- Do sufficient patients meet the *eligibility requirements* to make opening the trial worthwhile?
- Will the trial be available in community settings, or only at research hospitals?

### How effective are the accrual and retention plans?

- Are *research advocate* organizations involved?
- Are there adequate plans to reach out to *underserved* populations?
- Will excellent patient support materials that are culturally sensitive be provided (e.g., brochures, schedules, videos)?
- Does the *informed consent* process comply with best practices?
- Is ongoing patient support planned (e.g., scheduling, psycho-social consultation, pain management, peer support)?

### How attractive is the trial *protocol* from a patient's point of view?

- How effective is the *standard intervention*? (Note: Patients are less likely to volunteer for *clinical trials* when effective *standard interventions* exist.)
- Are alternative *clinical trials* available? How attractive are they?
- Will the trial extend the length of *treatment*?
- How many additional hospital stays, doctor visits, procedures, etc. will be required? How intrusive or inconvenient will these be?
- What are the financial consequences of participating in this trial? Which *interventions* and tests will be covered by the investigator? Will the patients' insurance companies pay for costs not covered by the investigator? Who will pay for *treatment* of side-effects? Will patients be compensated for travel and/or other expenses?
- Are physical accommodations available for patients who travel from out of town, or who have long lapses between procedures?
- How strong is the evidence that the *experimental intervention* will be effective? How much benefit is it likely to have?
- What are the likely and less likely side-effects of the *experimental intervention*? Are effective *treatments* available for these *side effects*? Are the *side effects* likely to resolve when *treatment* ends?
- How likely are unexpected long-term *side-effects* (e.g., secondary cancers, cognitive deficits) from the *experimental intervention*?

## How Well Designed Is The Trial to Answer The Questions It Addresses?

The acronym *PICO* is used by many researchers to organize the key elements of *clinical trial* design, and it will be used here. In particular, concepts are discussed and questions raised about each of the four *PICO* letters—**P**atients; **I**nterventions; **C**omparisons; and **O**utcomes.

### **PICO: Patient Issues**

Questions about which patients will participate in the trial (i.e., *eligibility requirements*) help establish that the results of the trial will be applicable to the population of patients whose *treatment* is likely to change if the trial is successful. They also help highlight the value of patients who volunteer to participate in clinical trials, and that like funding, patients are a limited resource.

### Are the *eligibility requirements* optimal?

- What are the pros and cons of making the *eligibility requirements* (e.g., disease site or stage, *biomarkers*, co-morbidities, prior *treatments*) more or less stringent?
- Would changes to the *eligibility requirements* increase participation of patients from *underserved populations*?
- How well do the *eligibility requirements* match the likely clinical use of the *intervention*, if the trial is successful?
- Is there an adequate patient *population* from which to accrue to this trial?



Does this design make the most efficient use of patients?

- Could the primary questions be answered with fewer patients?
- Is there a way to design the trial so that fewer patients are exposed to the less effective *interventions* (cf., section below on *patient allocation adaptive design*)?
- Is there a way to design the trial so that results could be achieved more rapidly?
- Could additional secondary questions be addressed without compromising the study?
- Can the study be modified to determine not only whether the *intervention* is beneficial, but also which patients are most likely to benefit?

How will patients be treated upon completion of the trial?

- Will patients who participated in the trial but did not receive the *experimental treatment* have subsequent access to the experimental treatment if it is found to be effective?
- Will the *experimental intervention* be made available to patients who did not receive it, if it is found to be effective?
- What long-term follow-up is planned?
- Will patients be informed about the results of the trial?

### PICO: Intervention Issues

The goal of a *clinical trial* is to determine the impact of an *experimental intervention* (used interchangeably with *investigational intervention*). When researchers plan the intervention, they focus primarily on its potential impact on the disease. When research advocates think about the *intervention*, on the other hand, we consider its impact on all aspects of patients' lives. This is important because patients who volunteer to participate in *clinical trials* deserve not only to receive excellent care, but also to be minimally inconvenienced. Further, from a practical point of view, aspects of the *intervention* that may have limited relevance to the disease (e.g., number of clinic visits), are important to patients and may impact trial accrual and retention, both of which are crucial for the success of trials.

Why was the *experimental intervention* selected?

- If this is a drug trial, what drug, dose, and schedule of administration will be used? What alternatives were considered?
- If this is not a drug trial (e.g., radiation, surgery, psycho-social, quality of life, correlative science intervention) what variations on the interventions were considered?
- What *supportive therapies* (i.e., drugs provided to counteract side effects) will be provided and under what circumstances?
- Under what circumstances will the drug dose or other aspects of the intervention be modified?

Are all of the test procedures (e.g., blood draws, scans, biopsies) necessary?

- Are less intrusive procedures available?
- How time consuming will these procedures be?
- Must all of the procedures be completed at the research center?
- Can the procedures be scheduled in a way that minimizes the number of trips a patient must make to the research center?

**PICO: Comparison Issues**

Assessing an *experimental intervention* requires comparing it to a *comparison intervention* (used interchangeably with *control intervention*). Questions about the nature of the *comparison* help establish that the trial is ethical. For example, for serious diseases for which useful therapies exist (e.g., many cancers), it is unethical to use *placebo comparisons*; rather *comparison groups* (used interchangeably with *arm*) typically receive the *standard of care*.

Additionally, to be able to conclude that the *experimental intervention* differs from the *control* requires that patients receiving different *interventions* are otherwise equivalent. Put another way, it is important to avoid any *bias* or *confounding* that might provide alternative explanations of *intervention effects*. Researchers generally focus on eliminating sources of *bias* that are related to the disease (e.g., stage of disease, prior *treatment*), whereas *research advocates* who think more holistically about patients often identify sources of *bias* that researchers may overlook (e.g., likelihood of remaining in the trial or complying with the *protocol*).

**Is the *control intervention* appropriate?**

- Is there a *standard of care* that will be prescribed, or will physicians be allowed to choose among *interventions*?
- Will researchers, health care providers, or patients know to which *intervention arm* patients were assigned (i.e., Is there *blinding*)?
- Will tests be performed on patients in both the *experimental* and *control arms*, even if they are not part of *standard care*? (Note: This provision is typically necessary to ensure *blinding*.)

**How will patients be allocated among *intervention arms*?**

- Are there ways in which patients assigned to different *interventions arms* may systematically differ (e.g., *demographics*, stage of disease)?
- What, if any, patient attributes (e.g., gender, disease site or stage) will be *stratified*? How were these factors chosen?
- What *demographic* and baseline *variables* will be measured to ensure that all groups were indeed equivalent?

**How will data be analyzed when the standard *protocol* is not followed?**

- If patients do poorly in the group to which they were assigned, will they be allowed to *crossover*?
- How will the *statistical analysis* deal with patients who crossover or drop-out of the trial? (i.e., question whether analysis is “intent-to-treat” or “what was actually received.”)

**PICO: Outcome Issues**

*Clinical trials* assess the effect of different *interventions* on the course of disease by measuring specific *outcomes*. The choices of *outcomes* or *endpoints* typically involve trade-offs that reflect priorities concerning speed, completeness, and clinical value. *Primary endpoints* (e.g., overall survival, disease free survival, proportion of responders) that are of highest interest are selected and the trial is designed to ensure that they can be adequately assessed. Additionally, secondary endpoints of lesser interest are specified in the protocol (e.g., side-effect profile, *quality of life*—QOL), but the trial may not be *powered* to adequately assess them.

*What is the primary endpoint?*

- Is it important to patients?
- Will it allow the trial to rapidly lead to results?
- Will it lead to definitive results?
- How will it be measured?
- Is the measure *reliable* and *valid*?
- What alternatives were considered and why was this one chosen?

*Surrogate endpoints* are *outcomes* that have been shown to be early indicators of clinical *outcomes* that are of interest (e.g. overall survival). An example is cholesterol which has been shown to predict heart attacks, and to be mechanistically related to them (i.e., by blocking arteries). The advantage of using *surrogate endpoints* is that they are available sooner than the *outcomes* for which they are *surrogates*, and hence allow trials to complete more rapidly and less expensively. Adequately demonstrating the appropriateness of a *surrogate* is, however, difficult. In trials that propose to use *surrogate endpoints* *research advocates* should ask:

*Why was this surrogate endpoint selected?*

- What clinically relevant *outcomes* are correlated with the *surrogate*?
- What is the evidence that impacting the *surrogate endpoint* will also impact the clinical *outcome* that is of primary interest?
- How will the *surrogate endpoint* be measured?
- Is the measure *reliable* and *valid*?

Additionally, many current *clinical trials* include the collection of a host of demographic and *biomarker* measures (sometimes referred to as secondary endpoints) that are analyzed in the hope of identifying questions worthy of future study. Analysis of these variables is called *correlative science*. Making sure that the *correlative science* associated with a *clinical trial* is as effective as possible could have large effect on future progress, and is worth probing in detail. While detailed consideration of these issues is beyond the scope of this tutorial, several basic questions to ask about the *correlative science* follow.

*What other variables (e.g., biomarkers, side effects, cognitive status, quality of life (QOL) and demographic variables) will be of measured?*

- How were they chosen?
- What alternatives were considered and why were these chosen?
- If *biomarkers* will be measured from bi-specimens (e.g., blood, tumor tissue), how will the bio-specimens be collected and handled? How will the *biomarkers* be assayed?
- How will they be measured?
- Are these measures *reliable*, *valid*, and clinically important?
- How will these data be analyzed and used?

Finally, a question always worth asking experts, not just about clinical trial designs, is:

*What other questions should I ask?*

### III. Introduction to Clinical Trial Design

**Figure 3. Francis Bacon (1561 – 1626)**



Father of Modern Scientific Method

While not essential, many *research advocates* are motivated to achieve a deep understanding of the research they try to influence. The purpose of this section is to present the logic and foundation that underlies clinical research. First the *scientific method* and its application to medicine are described. Then the key components of *randomized controlled trials* are discussed. The final subsection introduces hypothesis testing and some basic *statistical concepts* that are used by researchers to provide confidence in the *inferences* they draw from *clinical trials*.

#### The Scientific Method Applied To Medicine


*Evidence-based medicine* depends on the systematic accumulation of information about how different *treatments* affect patients. Ideally, a cause-effect relationship can be established between *treatments* and *outcomes* in patients with specific diseases. Francis Bacon (Figure 3) is often credited with being the father of the modern *scientific method*, which is the system underlying *evidence-based medicine*. It is based on *inductive methods* that can be used to draw general conclusions based on limited observation, in other words, using observations from a patient sample to draw conclusions about its patient population.

The scientific method is schematized in Figure 4 (page 12). The four key iterative stages are shown in the center, blue boxes:

- 1) **Observe Stage** which can entail both formal and informal observation.
- 2) **Hypothesize Stage** which articulates the research question in a testable format.
- 3) **Test Stage** which entails experimentation. *Clinical trials* are experiments that involve patients.
- 4) **Conclude Stage** that by validates or modifies the *hypothesis*. The conclusion generally leads to additional observation and experimentation.

The green clouds on the right side of Figure 4 provide examples of activities involved in each stage. Informed by their unique patient experiences, *research advocates* participate in all of these activities. The pink clouds on the left side of Figure 4 are the processes involved in moving through the four stages of the *scientific method*.

- 1) **Concept Development Process** assimilates observations from a variety of sources and frames a formal research question and testable *hypothesis*. In clinical research, this process often results in a trial concept document. The “what” and “why” questions raised in the previous section are particularly relevant to this process.
- 2) **Experimental Design Process** translates the research question about a population of interest into a formal experiment or *clinical trial protocol*. The *protocol* includes patient *eligibility requirements*, detailed descriptions of the *experimental* and *control interventions*, as well as definition of objective, measurable *outcomes*. The *PICO* questions raised in the preceding section are especially relevant to this process.
- 3) **Statistical Inference Process** is the process that allows researchers to draw conclusions about their *hypotheses*. The subsections below on “Hypothesis Testing and Statistical Inference” and on “Introduction to Bayesian Concepts” provide two alternative approaches to *statistical inference*.

**Figure 4. The Scientific Method**

Decisions about whether or not to proceed with the research are made between each stage in this schema. For example, *research advocates* have come to play an especially important role in reviewing grants that allocate funding; this occurs between the “hypothesize” and “test” stages.

Throughout the remainder of this tutorial a hypothetical *clinical trial* for patients with cancer of the big toe will be used. This example is used because it is concrete, but avoids the distractions associated with more realistic trials.

### Concept Development Example

Consider a clinician who treats patients with cancer of the big toe. In talking to a subset of her patients who had especially favorable *outcomes* (i.e., survive longer than typical), she noticed that many of them were big coffee drinkers. This raised the research question: “Does coffee drinking improve the survival of patients with cancer of the big toe?”

Research questions typically involve the four *PICO* components with the *patient* component is stated in terms of a target *population* that includes all current and future patients. Also, the *comparison* is often implicit.

The research question is translated into a testable *hypothesis* such as: Patients with cancer of the big toe, who drink coffee, survive longer than those who don’t.”

## Experimental Design (PICO) Example

An *experimental design* that can be used to test the research *hypothesis* is articulated in a *clinical trial protocol*. The *protocol* specifies the *eligibility requirements* of the sample of patients who will be studied, which is presumed to be representative of the population of interest in the research question. The protocol also provides details about the other *PICO* components. The details can be used by other researchers to interpret the results of *clinical trials*, or to replicate them.

For the cancer of the big toe example, the following design characteristics will be used throughout this tutorial.

<b>Patients</b>	<ul style="list-style-type: none"> <li>• Sixty patients (thirty each in the <i>experimental</i> and <i>control arms</i>)</li> <li>• Stage III cancer of the big toe</li> </ul>
<b>Intervention</b>	<ul style="list-style-type: none"> <li>• 500 mg. of caffeine</li> <li>• Administered orally</li> <li>• Twice a day for 90 days</li> </ul>
<b>Comparison</b>	<ul style="list-style-type: none"> <li>• 500 mg. of colored water</li> <li>• Administered orally</li> <li>• Twice a day for 90 days</li> </ul>
<b>Outcome</b>	<ul style="list-style-type: none"> <li>• Overall survival</li> </ul>

In many *clinical trials* the *control arm* receives no *intervention* or a *placebo*. However, because of the seriousness of the disease, in cancer *clinical trials* patients in the *control arm* typically receive the current standard of care, if there is one. Patients in the *experimental arm*, on the other hand, typically receive the same *Intervention* as the *control arm*, plus an additional *experimental intervention*, or an *experimental intervention* that is expected to be at least as effective as the *standard of care*.

In practice, *clinical trial protocols* go through many reviews and revisions (e.g., *Institutional Review Boards*) prior to opening for patient accrual, often including input from *research advocates*. In the conduct of a trial, circumstances often prevent perfect adherence to the *protocol*. For example, patients may skip a day of *treatment*, drop out of the trial, or some of their data may be missing. However, if the trial was carefully designed and run, *statistical inference* allows researchers to draw conclusions about the research question. This *inferential process* will be described below. First, however, a brief review of *randomized clinical trials*, the most common and useful trial designs will be presented.

## Randomized Controlled Trials

*Randomized Control Trials*, described in Figure 5, have become the gold standard of clinical research. To establish causality between the *intervention* (i.e., caffeine) and the *outcome* (i.e., overall survival), researchers assume and take steps to ensure that the experimental and *control arms* are similar in every way except the *interventions*. This is sometimes referred to as balancing the groups, and ensuring that no superfluous variables are *confounded* with the *intervention*. Three techniques to avoid confounding will be discussed.

**Figure 5. Randomized Clinical Trials: The “Gold Standard”**

Experimental/Investigational Group Arm	Comparison/Control Group Arm
Experimental or Investigation Treatment, plus Standard of Care	Standard of Care

- Equal number of patients randomly assigned to two or more treatment arms
- Triple blinded (patients, healthcare providers, and researchers), if possible
- Single primary endpoint
- May require many trials to answer complicated questions

1) **Randomization** assigns patients to *treatment arms* by chance, avoiding any systematic imbalance in characteristics between patients who will receive the *experimental* versus the *control intervention*. Usually patients are assigned equally to all *arms*, although this need not be the case. With a simple two-*arm* trial (one *experimental* and one *control*) randomization can be accomplished with a flip of a coin. When there are more than two *arms*, or unequal numbers of patients are to be assigned to different *arms*, computer algorithms can be used to ensure *random* assignment. The following example demonstrates the importance of *randomization*.

### Confounding Example

Consider a *clinical trial* in which overall survival is the outcome of interest. Suppose a large proportion of patients assigned to the *experimental intervention* have earlier-stage disease than patients assigned to the control arm. In this situation disease stage and *intervention* are said to be *confounded*.

Now suppose that patients who received the *experimental intervention* lived longer than patients who received the *control intervention*. Is the survival difference because the *experimental intervention* is truly better than the *control*? Or is it because patients in the *experimental arm* were healthier to begin with? There is no-way to determine which explanation is correct.

The difference in prognosis between *arms* in this trial could have arisen from many subtle *biases* in how patients were assigned to the *experimental* versus *control arms*. For example, healthcare providers may unconsciously assign sicker patients to the control intervention because they have more experience dealing with its *side-effects*. If patients were *randomized*, however, imbalances in disease stage would be highly unlikely, especially in large trials.

- 2) **Blinding** is ensuring that neither patients, healthcare providers, nor researchers know to which group specific patients are assigned. Trials are said to be single, double, or triple *blinded*, depending upon how many of the relevant participants in the trial are unaware of patient assignment. The purpose of *blinding* is to minimize patients receiving different care, or their data be interpreted differently, based upon the *intervention* they are assigned. The following example demonstrates the importance of *blinding*.

### Blinding Example

Consider a *clinical trial* in which it is suspected that an *experimental intervention* delays relapses compared to the *control intervention*, but is also more toxic. If this trial was not blinded, patients in the *experimental arm* might be especially vigilant to report toxicities. Likewise, their healthcare providers might unwittingly monitor these patients more closely than if they were assigned the *control intervention*.

Now suppose the *experimental intervention* was found to be more toxic than the *control*. Would this be due to a real difference in toxicity or reporting difference? There is no way to know. Had the patients and healthcare providers been *blinded* to which arm patients were assigned, this ambiguity would not have arisen?

- 3) **Stratification** prior to *randomization* can be used to ensure that the number of patients assigned to the experimental and control arms are balanced with respect to important attributes (*stratification variables*). Examples of *stratification* variables are gender or disease stage. The purposes of *stratification* are two-fold. First, *stratification* ensures that the *stratification variable* is not *confounded* with the *intervention*, which is especially important when the *stratification variable* is known to have a large impact on the outcome of interest. In large trials *randomization* alone typically achieves *balance*, and *stratification* may be unnecessary. Second, if adequately planned, stratification allows *sub-group analysis*, essentially looking at each stratum separately. It is not uncommon, however, for subgroup comparisons to be conducted even when not adequately planned. This leads to increased error rate, as discussed in the section on “Hypothesis Testing and Statistical Inference” below. The following example shows how *stratification* can help ensure that the results of a *clinical trial* can be interpreted.



## Stratification Example

Consider a *clinical trial* that is designed to test a new *treatment* believed to be beneficial for all solid tumors. The trial might include patients with lung, colon, and breast cancers. However since the disease process is so different among these tumors, patients might be *stratified* by disease site. In particular, patients with lung cancer will be *randomized* to either *experimental* or *control arms*, patients with colon cancer would be randomized to either *experimental* or *control intervention arms*, and patients with breast cancer would be *randomized* to either *experimental* or *control arms*.

In this example disease site is the *stratification variable*. It was selected because the natural disease course is known to be very different among these tumors. If *randomization* alone were used to assign patients to *interventions*, it is possible that a larger proportion of lung cancer patients (shortest average survival) might have been assigned to the *control arm*. This is fairly likely in small trials, but relatively unlikely in large trials.

In this example, if the *control arm* which included more patients with poorer prognoses had shorter survival, it would be impossible to determine whether it was due to the difference in *treatments* or the difference in patients. Prognosis aside, many interventions are found to be effective in only a subset of solid tumors, and stratification may make it simpler to identify such differences.

Detailed discussion of the drug development process is beyond the scope of this tutorial. Nevertheless, the various phases (0-IV) are defined in the glossary, several readings are recommended on this topic, and a few comments are in order here. First, *phase III trials* that are designed to prove the *efficacy* of new *treatments* all use randomized *controlled designs*, although many employ embellishments of the simple *two-arm design* discussed here. For example, there may be more than one *experimental arm*, perhaps with each *group* using a different new agent, or with each group using the same agent but at different doses. Second, given the different goals of phase I and II trials, alternative designs are often more appropriate. In particular, phase I trials are designed to determine safe drug doses and do not include *control groups*. Also, *phase II trials* are designed to establish drug activity. As a result, they are often small and preliminary, and often use *historical controls* rather than including a *randomized control arm*.

**Figure 6. Ronald Fisher (1890 - 1962)**



Father of Modern  
Statistical Analysis of  
Experiments

## Hypothesis Testing and Statistical Inference

After a *randomized controlled trial* is conducted, statisticians help determine whether any observed difference between *outcomes* in the *experimental* and *control arms* are real, or simply chance occurrences. Ronald Fisher (Figure 6) is often credited as the father of modern *statistical analysis* of *experiments*, in particular with defining the rules of *inference* that are used to assess the outcomes of *randomized controlled trials*. Interestingly, his methods were first applied in the 1920s to problems in agriculture, and are only today impacting educational practice. They began to be widely applied in medical research in the 1960s. This was largely due to the 1962 Kefauver-Harris Drug Amendment which required proof of *efficacy*, in addition to proof of safety for drug approval. Figure 7 shows the key components of *randomized controlled trials* in each of these disciplines.

**Figure 7. Introduction of Randomized Controlled Trials**

	Agriculture	Medicine	Education
Widespread Introduction	1920s	1960s	2000s
Samples	Plots of Land	Patients	Students, Classrooms, Schools
Example Interventions	Fertilizers	Drugs	Teaching Methods
Example Outcomes	Crop Yield	Survival	Student Learning

The process to which Fisher's methods can be applied is called *hypothesis testing*. In *hypothesis testing* a *null hypothesis* ( $H_0$ ) is articulated which is typically a statement of no difference between *experimental* and *control* patient *populations*. Articulation of the *null hypothesis* takes place in the first, concept development process of the scientific method described above.


## Null Hypothesis Example

The *null hypothesis* associated with the cancer of the big toe examples is: "There is no difference in the overall survival of patients with cancer of the big toe that are treated with caffeine versus treated with colored water."

More generically, the *null hypothesis* is typically: "There is no difference in the *outcomes* of patients treated with the *experimental* versus *control* *interventions*." The *null hypothesis* is about patient *populations*—all current and future patients with specific conditions who receive specific *interventions*. *Statistical inference* is used to decide whether or not the *null hypothesis* is true, based on a *sample* of patients in a *clinical trial*.

Next, the *clinical trial* is designed and run; this is part of the second, *experimental design* process of the scientific method described above. The third process in the *scientific method*—*statistical inference*—is outlined in Figure 8 (page 18). *Statistical inference* allows researchers to determine whether any observed difference between outcomes in the *experimental* and *control arms* reflects a true difference, or is simply a matter of chance.

**Figure 8. Statistical Inference in Hypothesis Testing**



When *clinical trials* data are analyzed, the *outcomes* of each *arm* is described using *descriptive statistics* such as *mean*, *median* and *standard deviation*. In addition, a *test statistic* (e.g., t-test or F-test) is computed and compared to the value this statistic would take, if the *null hypothesis* were true. The final step in *hypothesis testing* is deciding whether or not to reject the *null hypothesis*. When the computed *test-statistic* is different than what would have been expected if the *null hypothesis* were true, it is rejected; otherwise it is not.

**Statistical Inference Example**

Consider the cancer of the big toe example outlined on page 12. The following table provides descriptive statistics that might have resulted from this trial.

	<b>Experimental (Caffeine) Arm</b>	<b>Control (Water) Arm</b>
Sample Size	30	30
Mean Overall Survival	8.6	7.8
Standard Deviation	.6	.5

$t = 5.61, p \leq .01$

In addition to describing the results, a *t-test statistic* might be computed from the trial data. In this example, the t value is 5.61. This t-test would be compared to t-tests that result from the *null hypothesis* in trials with 30 patients in each of two *arms*. These values can be found in statistical tables. In particular, the tables indicate that a t-test  $\geq 2.65$  would have occurred by chance  $\leq 1\%$  of the time, if the *null hypothesis* were true. Since the t-test calculated from the trial data (5.61) is larger, the *null hypothesis* would be rejected, and researchers claim that survival is greater for patients who are treated with caffeine than with water.

The calculation of *test-statistics* is beyond the scope of this tutorial. However, three factors always influence their values, and hence how likely they are to deviate from *test statistics* that would have been computed had the *null hypothesis* been true. These are:

- 1) **Sample Size:** The larger the sample, the more likely the observed *outcomes* reflect their overall *populations*. The limiting case is when the entire population is part of the *clinical trial*. Thus, other factors being equal, the larger the *sample size*, the more likely the *null hypothesis* will be rejected.
- 2) **Variability:** The less *variability* among patients within each group, the more likely they reflect the overall *populations*. In trials with low *variability*, trial outcome differences between *experimental* and *control arms* are likely to be real (i.e., not due to chance). Thus, other factors being equal, the *null hypothesis* is more likely to be rejected in trials with low variability.
- 3) **Outcome Difference:** The larger the difference in *outcomes* between the *experimental* and *control arms*, the more likely there is a true difference, even if it is actually smaller or larger than observed in the trial. Thus, other factors being equal, the larger differences between *experimental* and *control arms*, the more likely the *null hypothesis* will be rejected.

How unlikely would the trial results need to be to reject the *null hypothesis*? This rests on researchers' tolerance for errors. The more tolerant of errors, for example, in more exploratory work, the more likely the *null hypothesis* will be rejected. However, it is never actually known whether or not the null hypothesis is true. Rather, researchers establish criteria to maintain specific error rates across all trials. This is what they do when they set  $\alpha$  or *type I error rates* at .5%, and  $\beta$  or *type II error rates* at 20%. Figure 9 and the following text explain these potential errors in more detail. This material is a rather technical and some readers may choose to skip to the judicial example at the end of this section.

The columns of Figure 9 provide the two possible true states of affairs: either the *null hypothesis* ( $H_0$ ) is true or false. The rows give the two possible decisions; either fail to reject or reject the *null hypothesis*. The cells show the conclusions that are drawn—either the *experimental* and *control groups* are equivalent or not—and whether the decision was correct (indicated by 😊), or an error (indicated by ☹️).

**Figure 9. Errors in Hypothesis Testing**

Truth/Decision	$H_0$ is True	$H_0$ is False
Fail to Reject $H_0$	😊 Ex = Control	☹️ Ex = Control
Reject $H_0$	☹️ ☹️ Ex ≠ Control	😊 😊 Ex ≠ Control

$\alpha$  or type I error
 $\beta$  or type II error

Decision rules are established to limit the percentage of trials with erroneous decisions. One type of error occurs when the *null hypothesis* is true but is rejected, (bottom, left cell). This is represented by two 😞😞 in Figure 9 because these errors can lead to serious consequences when new *treatments* are inappropriately adopted or future research is based on them. These errors are sometimes called false alarms or false positives because they falsely claim interesting differences between the *experimental* and *control groups*. They are also referred to as  $\alpha$  or *type I errors*, and decision rules are generally established to ensure they occur in no more than 5% of trials. However, when *sub-group analyses* are conducted, particularly if they were not planned prior to data collection,  $\alpha$  *error rates* can be much higher.

The other type of error occurs when the *null hypothesis* is false, but not rejected (top, right cell). These errors are sometimes called misses or false negatives because they occur when interesting, true differences between *experimental* and *control treatments* are missed. They are also referred to as  $\beta$  or *type II errors* and decision rules generally ensure that these errors will occur in no more than 20% of trials.

There are also two types of correct decisions. One is when the *null hypothesis* is false and it is rejected (lower, right-hand cell). In this case, sometimes referred to as a hit, the correct decision is that there is a true difference between the experimental and control arms. This is represented by two 😊😊 in Figure 9 because this is the goal of most *clinical trials*—to identify new, effective treatments. *Clinical trials* are designed so that the *null hypothesis* will be rejected in 80% of cases in which it is false—that is, when  $\beta$  *errors* are not made. This probability of correctly rejecting a false *null hypothesis*, and in so doing identifying a true *treatment* difference, is referred to as power, and is always equal to  $(1 - \beta)$ .

The cells with 😊 reflect the other type of correct decisions—failing to reject the *null hypothesis* when it is true (top, left-hand cell). In these cases the *clinical trial* does not provide adequate evidence to conclude that there is any difference between the *experimental* and *control arms*. Although many researchers conclude the two *treatments* are the same, such a conclusion is actually a stronger conclusion than is justified.

## Judicial Inference Example

It may be helpful to compare *statistical inference* used in *hypothesis testing* to the judicial inference process involved in criminal trials. The presumption that the defendant is innocent until proven guilty is equivalent to the *null hypothesis*. Requiring “evidence beyond a reasonable doubt” to convict a defendant is aimed at minimizing the chances of convicting innocent defendants. This is akin to minimizing *type I errors* ( $\alpha \leq .05$ ) in a *clinical trials*. Further, while there is a desire to avoid acquitting guilty defendants, doing so is somewhat more tolerated. This is akin to the somewhat higher tolerance of making *II errors* ( $\beta \leq .20$ ) by failing to reject a false *null hypothesis*.

The four possible *outcomes* of jury trials are compared to the *outcomes* of *clinical trials* in the table below. Note that the decision in the *clinical trial* is always relative to the *control (standard of care) intervention*.

	<b>Jury Trial</b>	<b>Clinical Trial</b>
$H_0$	Presumed Innocence	Experimental = Control
Correctly Reject the $H_0$	Convict a felon intervention	Identify effective
Correctly Fail to Reject the $H_0$	Acquit an innocent	Correctly reject ineffective intervention
Type I Error	Convict an innocent intervention is effective	Claim an ineffective
Type II Error	Acquit felon	Miss an effective intervention

Although the judicial analogy may be helpful in conveying the logic of *hypothesis testing*, it remains a rather contorted process. An alternative approach based on *Bayesian statistics* is more natural and gaining influence in medical research. The Bayesian approach will be discussed in the next section of this tutorial.




## IV. Innovations in Trial Design

The “Introduction to Clinical Trials” section focused on the current standard practice of *clinical trial* design. Innovative approaches, while not yet widely used, will be discussed here because they have potential to significantly advance the field of *clinical trial* design, and lead to more rapid progress in identifying effective cancer *treatments*. As discussed above, *clinical trial* design entails balancing competing priorities (Figure 1). Traditional trial designs have maintained the highest priority on avoiding *type I errors*. To accomplish this, trials are very large and costly, and generally require many years to provide answers. The innovations discussed in this section also place high priority on avoiding incorrect conclusions, but often require fewer patients and dollars to complete the trials, and lead to results more rapidly. Therefore, they should be of interest to *research advocates*.

### Introduction to Bayesian Concepts

**Figure 10. Thomas Bayes (1702 -- 1761)**



*Bayesian* concepts are not new. Thomas Bayes (Figure 10) lived in the eighteenth century, hundreds of years before Ronald Fisher worked on modern *statistical methods*. Among other issues (c.f., Winkler, 2001), the computational complexity involved in the Bayesian approach made it impractical to implement his ideas. Given advances in computer technology over the past thirty years, the *Bayesian* approach has become more practical.

Increasing practicality of using the *Bayesian* approach, on the one hand, paired with increasing recognition of problems associated with the traditional approach (c.f. Goodman, 2001), on the other hand, are likely to result in a *paradigm shift* characterized in Figure 11. The different *inferential processes* that are used and questions that are addressed by traditional (generally referred to as *frequentist*) and *Bayesian approaches* are shown in the top half of Figure 11, and will be discussed below. This *paradigm shift* will significantly impact drug development, as shown in the bottom half of Figure 11. First, drug approval will come to be based on “weight of evidence” rather than “pivotal trials,” as is currently the case. Second, this is likely to lead to a glossing of the phases of drug testing (*phase I – III* trials). Third, *adaptive designs*, discussed below, will be the vehicle of this glossing of the phases. Fourth, trials will be analyzed using *Bayesian* statistics.


**Figure 11. Paradigm Shift**

	Old	New
<b>Inferential Process</b>	Hypothesis Testing (Attempt to reject <i>null hypothesis</i> )	Continuous Learning (Update probabilities of alternative <i>hypotheses</i> )
<b>Question Being Addressed</b>	How likely are the trial results, given there really is no difference among treatments?	How likely is there a true difference among treatments, given the trial data?
<b>Drug Approval</b>	Pivotal Trial Distinct Phase 0-IV Trials	Weight of Evidence Continuous Trials
<b>Trial Designs</b>	Single Stage	Adaptive
<b>Statistics</b>	Traditional	Bayesian



The overall conceptual model of the *scientific method* (Figure 4) holds for both *Bayesians* and *frequentists*. Likewise, the issues of randomization and blinding hold for both approaches. However, the *Bayesian* approach provides an alternative process for carrying out the inferential steps that allow researchers to draw conclusions about populations of patients, based on samples in their trials. The *Bayesian inferential process* will be described below, and contrasted to the process employed by *frequentists* that was described in the previous section. Although the frequentist approach has been widely used, the logic is quite contorted. Further, progress has been slow because trials are large and expensive.

**Figure 12. Bayes' Theorem**



Why are *Bayesian trials* generally smaller and hence less costly? *Bayesians* build on prior knowledge, rather than viewing each trial in isolation. Prior knowledge, for example, may be based on trials with similar drugs in different organ sites or disease stages. The concept of incorporating pre-trial knowledge is captured in Bayes' Theorem which is presented in words in Figure 12. At the start of a trial, a Bayesian will assign a *prior probability* to the *hypothesis* of interest, based on the best information available at that time. The trial data will be used to calculate the *standardized likelihood*, which will be combined with the *prior probability* to yield a *posterior probability*, which can in turn be used as the starting point (i.e., *prior probabilities*) of subsequent trials. In this way, the *Bayesian* approach is sometimes said to embrace continuous learning.

Three examples of the *Bayesian* approach are provided below. The first concerns betting on sporting events, and demonstrates that incorporating prior knowledge—in this example, prior success of a football team—is natural to the way people think. The second example is a diagnostic example in which prior knowledge about the *prevalence* of different diseases, and the *specificity* of diagnostic tests are taken into account to arrive at the most likely diagnosis. The final example builds on the “cancer of the big toe” example outlined above, and demonstrates how information from prior trials might be incorporated into *clinical trials*.

## Bayesian Sports Example

College football seasons consist of twelve regular season games. At the beginning of the season, a sports fan is generally undecided about the strength of her favorite team. As the season progresses she is likely to become more or less confident of a win, based on the team's success during previous weeks.

In Bayesian terms, the fan's *prior probability* at the beginning of the season was around .5. Following the first game, her *posterior probability* would be smaller if her team lost the season opener, and larger if they won. That *posterior probability* computed after game one would be used as the *prior probability* for considering the second game of the season, and so on throughout the season.

If the fan was a betting person, her money would follow Bayesian logic. For example, if her team won the first ten games, her *prior* and *posterior probabilities* would increase throughout the season, and she would be likely to bet on a win in game eleven. On the other hand, if the team had only won half of the first ten games, her *prior* and *posterior probabilities* would fluctuate around .5 throughout the season, and she would be hesitant to bet on a win in game eleven.

For illustrative purposes, the success of last year's season, the strength of each week's opponents, and whether or not games were played at home, were not incorporated into this example. The *Bayesian* framework could, however, accommodate them, as well as other relevant information.

The key point is that a team's football games are not independent events, and thus history influences betting. The same, according to *Bayesians*, can be said about clinical trials that involve similar diseases or *treatments*.

## Bayesian Diagnostic Example

There are typically many possible causes associated with any set of symptoms. An initial diagnosis is generally the most common or *prevalent* disease that matches the symptoms. Thus, for example, the common cold is a much more likely diagnosis of a cough than is lung cancer. If the initial diagnosis turns out to be wrong, for example because the cough persisted, tests may be run to refine the diagnosis. In this example, a chest CT might be ordered.

If a suspicious spot is found on the CT scan, a patient may fear the worst and assume she has lung cancer. This concern is especially likely in smokers who have a higher *prior probability* of having lung cancer.

In actuality, a lung cancer diagnosis would be premature, even in smokers, because the *specificity* of a chest CT for lung cancer is rather low. That is, there are many causes of spots on lung CTs (e.g., pneumonia) that have higher *prior probabilities* than lung cancer. Only when these are ruled out would a biopsy, which is a definitive but highly invasive test, be done to establish a correct diagnosis.

To summarize, the prevalence of potential diseases are used to establish *prior probabilities*. The results of diagnostic tests are factored in to provide *posterior probabilities*, which can then be used as *priors* for subsequent tests, until a definitive diagnosis is established.

## Bayesian Clinical Trial Example

Consider the hypothetical cancer of the big toe trial outlined on page 14. Researchers *hypothesized* that the *experimental intervention* (i.e., caffeine) is superior to the *standard of care* (i.e., water) in treating cancer of the big toe. In the *Bayesian* framework a *prior probability* would be assigned to this *hypothesis*. For example, based on previous experience (e.g., trials in thumb cancer), they might assign a *prior probability* of .6 to this *hypothesis* (i.e., the *probability* that caffeine is better than water is slightly better than even chance).

After collecting data, the researchers would calculate a *posterior probability* which becomes their new best guess about the *hypothesis*. In this example, suppose patients who were treated with caffeine lived an average of 8.6 years following treatment, whereas those treated with water lived an average of 7.8 years. This would provide confirming evidence for the *hypothesis*, and the *posterior probability* would be higher than the *prior probability*, (e.g., perhaps .8). On the other hand, if patients in the *control arm* survived longer than those on the *experimental arm*, the trial would cast doubt on the *hypothesis*. In such cases the *posterior probability* would be lower than the *prior probability* (e.g., perhaps .5 or even less).

In this way new beliefs about the *hypothesis* (i.e., *posterior probabilities*) combine prior knowledge (i.e., *prior probability*) with trial data. The larger the trial and the greater the difference between the *experimental* and *control arms*, the greater the influence of the trial data on the new belief about the *hypothesis*.

While the calculations used in the *Bayesian approach* are beyond the scope of the current tutorial, the above examples should have provided the reader with a sense of how existing knowledge can be incorporated into the *inferential process*, as well as the naturalness of the approach. In everyday life as well as the clinical setting, very surprising results are almost always discounted. This is consistent with the *Bayesian*, but not the *frequentist* approach.

A major criticism of the *Bayesian approach* is the apparent subjectivity associated with establishing *prior probabilities*. Who gets to decide which pre-existing data to incorporate and how heavily to weigh them? While not trivial, there are ways around these issues. First, non-informative *prior probabilities* could be used. A non-informative *prior probability* would be equivalent to chance, for example, .5 in a two-*arm* trial. Second, the same decisions about a *hypothesis* are often reached for a wide range of *prior probabilities*. Third, in large trials, new data tend to overpower any influence of *prior probabilities*.

Other differences between *frequentists* and *Bayesians*, besides the use of prior information, are summarized in Figure 13. On the one hand, *Bayesians* use Bayes' Theorem to address questions and draw conclusions that are framed as *probabilities* associated with various hypotheses. *Frequentists*, on the other hand, use *statistical methods* (i.e., *sampling distributions* of *test statistics*) that support *hypothesis testing* and limit error rates.

These differences have important consequences. First, *Bayesians* draw conclusions about *hypotheses* of interest, rather than the *null hypothesis*. Second, *Bayesians* can use same data to assess multiple *hypotheses*. Third, and perhaps most important, *Bayesians* do not have the same concerns about error rates that plague frequentists. This difference is because *Bayesians'* conclusions are *posterior probabilities* that are neither right nor wrong, but rather estimates about the correctness of *hypotheses*. *Frequentists*, on the other hand, reject or fail to reject the *null hypothesis*, and are thus either right or wrong. Unfortunately, in any given trial they do not know which. Therefore, *frequentists* go to great lengths to limit the overall number of errors, especially *type I errors*. This strategy, in turn, leads *frequentists* to limit the number of times they look at their data. *Bayesians*, on the other hand, have no difficulty looking at their data as they are being collected, and even using interim results to modify trials. This technique can have major impact on the value and timeliness of *clinical trials*, as well as on their efficiency. The opportunity to continuously monitor data and modify trials as they are accruing is the basis of *adaptive designs* which will be discussed in the next subsection.

**Figure 13. Frequentist versus Bayesian Approaches**

	Frequentists	Bayesians
Inference Rule	Sampling distribution of test statistics, under the <i>null hypothesis</i>	Baye’s Theorem
Questions	How unlikely is the experimental result, assuming the <i>null hypothesis</i> is true?	How likely are various <i>hypotheses</i> given the experimental results?
Conclusions	Reject or fail to reject the <i>null hypothesis</i>	Probability of alternative <i>hypotheses</i>
Prior Information	Not relevant	Can be incorporated
Key Challenges	Limiting $\alpha$ and $\beta$ errors	Justifying <i>prior probabilities</i>

By discussing *Bayesian* approaches with researchers, *research advocates* can play a role in accelerating the *paradigm shift* described in Figure 11. While it would be a mistake to advocate an immediate adoption of this approach, it is not too soon to encourage the research community to learn about it. As people become more educated in the uses and abuses of *Bayesian* methods and develop simple software tools to implement them, their strengths and limitations will become more apparent.

### Introduction to Adaptive Designs

The term “*adaptive design*” is used in many different ways. Here it is used to describe any multi-stage trial where later stages are based, in part, on what happened in earlier stages. While a *Bayesian* perspective is not strictly necessary for adaptive designs, as discussed above these designs are natural to *Bayesians* who are constantly updating *probabilities* and comfortable continuously looking at their data. Therefore, adapting trial designs as data accumulate is consistent with their paradigm. This is not really the case for *frequentists* who draw *inferences* from isolated trials and control error rates. Still, *frequentists* are increasingly using multi-stage designs because of their appeal. However, this is straining the traditional *paradigm* and is likely to eventually give way to the *paradigm shift* described in Figure 11.

## Adaptive Method Example

By using information as it accumulates, adaptive designs allow researchers to focus their data collection on issues that require the most attention and/or reduce the overall amount of data they collect.

Vision and hearing tests use adaptive methodologies and provide an intuitive sense of the value of *adaptive trial designs*. In both of these tests initial assessments are similar for all patients, and are designed to rapidly find the general limits of vision or hearing. Later assessments, however, are individualized and designed to fine-tune the necessary vision or hearing correction.

Likewise, *adaptive trials* are often designed to first establish general characteristics of the trial, and then to focus data collection where it will be most informative. For example, some *adaptive trials* begin by comparing several drugs or drug doses and through the course of the trial focus on the two that appear to be most beneficial.

There are many modifications that can be made during the course of an *adaptive trial*. For example, an adaptive sampling rule can determine how many subjects should be included at subsequent stages of a trial. This rule may be based on accumulating information about accrual rate, *sample variance*, or availability of funding. Alternatively, a stopping rule would establish under what conditions the trial should be terminated, for example, due to observed efficacy, harm, futility, or safety. Several examples of potential *adaptation rules* are provided below.

## Adaptation Rule Examples

**Sampling Rule:** Compute the *standard deviation* of the sample after the *outcome* is measured in the first ten patients.

- 1) If the *standard deviation* is larger than assumed in planning the trial, recruit more patients than previously planned.
- 2) If the *standard deviation* is smaller than assumed in planning the trial, recruit fewer patients than previously planned.

**Stopping Rule:** Compute the *test statistic* after the *outcome* is measured in the first ten patients.

- 1) If the *test statistic* suggests that the *experimental intervention* is inferior to the *control intervention*, with less than a 5% chance of this being due to chance, stop the trial for futility.
- 2) If the *test statistic* suggests that the *experimental intervention* is superior to the *control intervention*, with less than a 1% chance of this being due to chance, stop the trial due to *efficacy*.

Whatever the *adaptation rules*, they must be specified prior to starting the trial. This requires a considerable amount of time and thought should be given to planning adaptive designs, but these upfront costs are typically more than made up by the time the trial is completed.

The remainder of this section will present three specific multi-stage designs that in varying ways, use information obtained in early stages of the trial to modify later stages. They are: 1) *patient allocation adaptive design*; 2) *patient preference design* and 3) *randomized discontinuation design*. In addition, patient enrichment strategies, which can also increase the efficiency of *clinical trials*, will be introduced.

### Patient Allocation Adaptive Design

In the patient *allocation adaptive design* an *adaptation rule* modifies the way patients are assigned to *intervention arms* as a result of accumulating data. Patients are always assigned *randomly*; what is modified is the proportion of patients assigned to each *intervention arm*. In particular, more patients are assigned to the *intervention* that is performing better. If the apparent advantage is real, the *intervention arms* rapidly diverge and the trial can be concluded. However, if the advantage is due to chance, the *intervention arms* converge. The total number of patients needed to come to a reliable conclusion is determined as data accumulate, but it is typically fewer than with a traditional one stage design. Additionally, compared to the traditional *randomized controlled trial*, a larger proportion of patients in the *patient allocation adaptive design* are treated with the superior *intervention*. Don Berry, Ph.D. of MD Anderson Cancer Center has used this design effectively in a number of applications, and his simulations demonstrate its efficiency in finding “winners” among a group of potential interventions.

### Patient Allocation Adaptive Design Example

Figure 14 (page 30) presents an example of a two-arm trial in which assignment of patients to intervention is modified through the course of the trial. The *adaptation rule* specifies that at the start of the trial patients should be allocated equally to the two treatment arms. The *adaptation rule* also indicates when data should be analyzed, and depending on the results, how the allocation ratio should be changed.


In this example, data were analyzed after *outcomes* from the first eight patients became available. The response rate (i.e., percentage of patients whose tumors shrink following treatment) was twice as large in one of the *arms*. The *adaptation rule* specified that in such cases, the ratio of patient assignment should change from 1:1 to 3:1, favoring the superior arm.

As more data are collected *outcomes* would continued to be compared at pre-specified points. The adaptation rule would specify under which condition the trial should be:

- 1) terminated due to clear superiority of one treatment;
- 2) ended due to clear equivalence of the *treatments* (i.e., futility of finding difference)
- 3) continued, with the same patient allocation; or
- 4) continued with a revised patient allocation.

Note that throughout the trial, all patients were randomly assigned to the *experimental* and *control arms* based on a randomization algorithm, even though the proportion of patients assigned to each arm shifted through the course of the trial.

Figure 14. Patient Allocation Adaptive Design



A serious limitation to *patient allocation adaptive designs* is the need for an *outcome* measure that occurs relatively quickly before many new patients accrue. An example of where these designs might work well is with an outcome measured at a landmark time, such as, tumor response measured at four months after beginning protocol therapy, engraftment measured six months after transplantation, or *biomarkers* (used as *surrogate endpoints*) measured at a specific time after receiving drug. Another possible application is with survival endpoints; however, due to the time-sensitive nature of the design, it might be most appropriate for poor prognosis patient subgroups, like those with pancreatic cancer or those receiving salvage therapy for metastatic disease.

Consider an approach to both cancer research and *treatment* that might be called a “continuous *adaptive trial*.” All patients could be treated as part of an *adaptive trial* that includes all *treatments* that are likely to be at least as effective as the *standard of care*. As new *treatments* reach this criterion, they would be added to the set of *treatments* included in the trial. As data accumulate, *treatments* that do not perform well would be removed. Essentially, this would be one large trial that included all *treatments* currently in *phase II, III* and *IV* trials, as well as the *standard of care*. While a revolutionary idea, this would be a sound evolutionary approach to improving the *standard of care*. Although conceptually simple, it would, no doubt, be difficult to implement. It is unlikely that many pharmaceutical companies would be willing to participate in such trials. Patient safety would need to be addressed and adjustments to regulatory processes would also have to be considered. Still, it may be worth discussing such an approach. There seems to be the potential for significant improvement in the *treatment* of patients, as well as more rapid research progress.

### Patient Preference Design

Another literally “out of the box” *adaptive design* is sometimes referred to as the *patient preference design* (Figure 15). It is motivated, in part, by distaste for *randomization* among many potential participants in *clinical trials*. Using this design, patients can agree to be in trials, and then can select to either be *randomized* or not. The *adaptation rule* for this trial would specify how many patients to recruit and when to stop the trial based on:

- 1) proportion of patients who select their own *intervention* versus those who choose to be randomized;
- 2) overall *outcome* differences between the *experimental* and *control arms*; and
- 3) similarities of *outcomes* in patients who select their own *treatment* versus choose to be *randomized*.

### Patient Preference Design Example


Figure 15 presents an example of a two-arm *patient preference design*. Patients agree to participate knowing that they will have the option to select their own treatment, among those included in the trial, or be *randomized*.

Patients who have no *treatment* preference fall into the top row of Figure 15, which is essentially the traditional two-arm *randomized controlled trial* design. Patients who want to choose their own treatment would not be allowed to participate in a traditional trial, but are included in trials that use *patient preference designs* (i.e., the bottom row in Figure 15). Including patients who want to select their own *treatment* allows the trial to accrue more rapidly.

*Statistical analyses* can be used to determine whether the option to select *treatment* had any influence on *outcomes*—that is, whether the pattern of outcomes differs in the two rows of Figure 15. If the same *treatment* is superior regardless of whether or not patients select it, which is most likely to be the case, the trial can be completed with fewer *randomized* patients than would have been required in the traditional design.

If the difference in *outcomes* varies depending on whether or not patients select their own *treatment*, either in direction or magnitude, that finding itself would be of interest. It might, for example, suggest that patients are more compliant with *treatments* they actively choose. Such a finding would not be possible to detect in traditional *randomized controlled trials*.

Figure 15. Patient Preference Design





### Patient Enrichment Strategy

One of the difficulties of cancer research is that even among patients with the same diagnosis (e.g., stage IV breast cancer), different patients respond to different drugs. The challenge then is to identify patients most likely to respond to each new *intervention*. This requires framing research questions in terms of the sub-group of patients who are most likely to respond, and establishing *eligibility requirements* that restrict trials to this target group. This strategy is referred to as *patient enrichment*. As cancer *interventions* become more targeted, patients who are most likely to benefit from each new *intervention* can be selected based on *biomarkers*—for example, DNA or RNA in their tumor or circulating cells, proteins in their blood, or genetic factors that influence the way they metabolize drugs. The following example indicates the advantage of using a *patient enrichment* strategy when a relevant *biomarker* is known.

### Patient Enrichment Example

Approximately one-third of breast cancer tumors over-express a gene called HER<sub>2</sub>, and as a result have more HER<sub>2</sub> receptors on their cells. These tumors grow more aggressively and result in poorer prognoses. Trastuzumab, a drug commonly referred to as Herceptin, is a targeted therapy that binds to HER<sub>2</sub> receptors. Rather than testing its *efficacy* in all breast cancer patients, initial trials were restricted to patients who over-expressed the HER<sub>2</sub> gene.

This was a *patient enrichment* strategy that allowed researchers to demonstrate the benefit of the *treatment* in a select subset of patients. The drug was approved for use in patients who over-express HER<sub>2</sub>. Subsequent trials confirmed that this drug has limited *efficacy* in women who do not over-express HER<sub>2</sub>. Had the initial trials not utilized a *patient enrichment* strategy it is unlikely that the drug would have been shown to be effective. This is because it is ineffective in approximately 85% of breast cancer patients—those approximately 65% who do not over-express HER<sub>2</sub>, as well as 50% of those who do express HER<sub>2</sub>, but do not respond to the drug.

### Randomized Discontinuation Design

It is not always possible to predict which patients are most likely to respond to new *treatments*. The *randomized discontinuation design* uses a *patient enrichment* strategy in a *two-stage design*, even when there is no way to predict which patients are most likely to benefit from the *experimental intervention*. It is particularly useful in *phase II trials* where establishing a drug's activity is at issue.

## Randomized Discontinuation Design Example

Figure 16 presents an example of a trial that uses a *randomized discontinuation design*. Initially all patients in this trial receive the *experimental intervention*; this is often attractive to prospective volunteers.


The *adaptation rule* specifies that patients' tumors are measured six weeks after their *treatment* begins. Further, their treatment may be modified according to the following rule.

- 1) Patients for whom the *experimental intervention* appears to be working—i.e., their tumors shrink—continue on the *experimental intervention*
- 2) Patients who do not appear to be benefiting from the *experimental intervention* are switched to the *standard of care*
- 3) Patients who have stable disease are *randomized* to continue the *experimental intervention* or switch to the *standard intervention*. These two randomized groups essentially form the traditional two-arm randomized controlled trial.

Evidence of *treatment activity* can come from two sources in this design. First, if a significant proportion of patients fall into first group above, the *treatment* is likely to have value. The second source of evidence comes from the *randomized* portion of the trial (i.e., third group above). If patients in the *experimental arm* of have superior *outcomes* to those in the control arm, there is also evidence of activity.

Assuming activity is identified, the challenge is to predict which patients are most likely to benefit. This is an important goal of the *correlative science* associated with many *clinical trials*.

Figure 16. Randomized Discontinuation Design



### Summary: Adaptive Design

There are numerous ways to modify the traditional randomized controlled trial design as it accrues. The examples presented here were used to introduce some key design concepts. They also provide a sense of the types of innovations that are possible, and how they might influence patients and research progress. The questions presented in the “Questions to Ask about Clinical Trials Section” are as applicable to adaptive designs as to traditional designs. Advantages of adaptive designs often come at the cost of increased complexity and opportunity for abuse. Thus, in evaluating adaptive designs it is useful to keep in mind the following points, and raise questions about them:

- All aspects of *adaptive designs*, including all adaptation rules, must be fully specified **prior** to starting the trial.
- While some aspects of the design may not entail randomization (e.g., the first stages of the *patient preference* and *random discontinuation designs*), virtually all sound designs include some **randomization**.
- *Randomization* does **not** require equal numbers of patients in each *intervention arm*; however, a random process must assign individual patients to *intervention arms* in the desired proportion.
- Although *frequentists* may use *multi-stage designs*, they exact a severe penalty on power that diminish the efficiency gained by *adaptive designs*.
- Continuous data monitoring and adaptation is natural to *Bayesians* since they are interested in continuously updating *probabilities*, rather than determining “absolute truth.”

## V. Conclusions

This tutorial was developed to provide *research advocates* with a basic understanding of the *scientific method* and two alternative inferential processes used to establish *evidence-based* clinical practice from *clinical trials*. Given this understanding, *research advocates* should be able to contribute to this process. While not experts in science, *statistics* nor trial design, research advocates have a unique contribution to make because they focus on the whole patient experience, have a sense of urgency about making progress, and are not afraid to ask naïve questions. Finally, the tutorial described a *paradigm shift* (Figure 11) that is underway in *clinical trials*. *Research advocates* are encouraged to become more knowledgeable by asking questions and continuing to read about these topics. The recommended reading list that follows should assist in this endeavor.

## VI. Acknowledgements

Funding for this tutorial was provided by the Department of Defense Center of Excellence Grant in Breast Cancer Research at Indiana University to the Research Advocacy Network Advocate Institute. Copies can be downloaded from the Research Advocacy Network website at [www.researchadvocacy.com](http://www.researchadvocacy.com).

### Reviewers:

We gratefully acknowledge the important role and dedication of significant time to review the tutorial:

- Connie Cirrincione, MS, Cancer and Leukemia Group B Staff Statistician
- Mary Elliott, Breast Cancer Advocate
- Susan Nathanson, PhD, Breast Cancer Advocate and former Executive Director, Y-ME National Breast Cancer Organization
- Anne O'Neill, MS, Eastern Cooperative Oncology Group
- Elda Railey, Co-Founder Research Advocacy Network
- Mary Lou Smith, JD, MBA, Co-Founder Research Advocacy Network

Appreciation is also expressed to the following for additional feedback and advice to the author:

- Dan Hayes, MD, University of Michigan
- Marion Perlmutter, PhD, University of Michigan
- Don Berry, PhD, MD Anderson Cancer Center

### Research Advocacy Network

The Research Advocacy Network is a non-profit organization working to bring together all participants in the medical research process with the focus on education, support and connecting patient advocates with the research community to improve patient care. The Research Advocacy Network has started the Advocate Institute to educate and equip patient advocates with basic scientific knowledge and a better understanding of the research system. The Institute employs the newest technologies to facilitate knowledge transfer.

### Jane Perlmutter, PhD

Jane Perlmutter is a consultant-evaluator for the Higher Learning Commission and a frequent facilitator for its Academic Quality Improvement Program Strategy Forums and other programs. She has numerous publications and a Distinguished Teaching Award. Her formal education includes Masters degrees in Educational Psychology and Computer Science, and a Ph.D. in Cognitive Psychology from the University of Massachusetts in Amherst. She also received an MBA from New York University's Executive Program. Jane is a long-term breast cancer survivor and research advocate. She can be contacted at [janep@gemini-grp.com](mailto:janep@gemini-grp.com).

## VII. Recommended Readings

### Introductory Statistics

Gonick, L., Smith, W. *Cartoon Guide to Statistics*. Harper, 1993.

### History of Statistics

Salsburg, D. *The Lady Tasting Tea: How Statistics Revolutionized Science in the Twentieth Century*. W. H. Freeman, 2000.

### Drug Development

Coalition of National Cancer Cooperative Groups. *Cancer Research: A Guide to Clinical Trials—Drug Development*. [www.cancertrialshelp.org](http://www.cancertrialshelp.org), 2001

FDA. *From Test Tube To Patient: Protecting America's Health Through Human Drugs*. <http://www.fda.gov/fdac/special/testtubetopatient/default.htm>, 2006.

NCI. *Clinical Trials Education Series*. <http://www.cancer.gov/clinicaltrials/learning/clinical-trials-education-series>, 2001.

### Bayesian Statistics

Berry D.A. (2006). Bayesian Clinical Trials. *Nature Reviews: Drug Discovery*. 5: 27-36; 2006.

Goodman, S.N. Toward Evidence-Based Medical Statistics: The P Value Fallacy. *Annals of Internal Medicine*. 130:995-1021; 1999.

Spiegelhalter D.J., Keith R., Abrams K.R., Myles J.P. *Bayesian Approaches to Clinical Trials and Health-Care Evaluation*. John Wiley & Sons, Ltd. 2004.

Winkler, R.L. Why Bayesian Analysis Hasn't Caught on in Healthcare Decision Making. *International Journal of Technology Assessment in Health Care*. 17:1, 56-66; 2001.

### Adaptive Designs

Gallo P, Chuang-Stein C., Dragalin V., Gaydos B., Krams M., Pinheiro J. Adaptive Designs in Clinical Drug Development—An Executive Summary of the PhRMA Working Group. *Journal of Biopharmaceutical Statistics*. 16: 275–283; 2006.

## VIII. Glossary

<b>Concept</b> <b>Alpha (<math>\alpha</math>) Error</b>	<b>Definition</b> In a test of a statistical hypothesis, the probability of rejecting the null hypothesis when it is true. Also called a type I error or false positive.
<b>Adaptation Rule</b>	Pre-specified rule that defines how an adaptive trial may be changed. Examples include changing the allocation of patients to treatment arms, changing the total number of patients that will be recruited, adding or deleting treatment arms, or stopping the trial early.
<b>Adaptive Design</b>	Multi-stage design in which some aspect of later stages of a trial depend, in a pre-defined way, upon what happens during earlier stages of the trial.
<b>Adaptive Trial</b>	Clinical trial that employs an adaptive design.
<b>Analysis of Variance (ANOVA)</b>	A statistical method to assess whether the amount of variation in a process is significant or caused by chance.
<b>Arm</b>	Any of the treatment groups in a clinical trial. Many randomized trials have two arms—one experimental and one control—but some have three or more “arms.” Some phase II trials have only one arm.
<b>Balanced</b>	In trials with two or more treatment arms, ensuring that all treatment arms have approximately the same proportion of patients with a given characteristic, for example, gender or race.
<b>Bayesian Approach</b>	A form of statistical reasoning that is based on continuously learning or updating the probabilities associated with an event. In particular, prior probabilities are modified in the light of data or empirical evidence in accordance with Bayes’ theorem to yield posterior probabilities, which may then be used as prior probabilities for further updating in the light of subsequent data. This increasingly popular method represents an alternative to the traditional (or frequentist probability) approach: whereas the latter attempts to establish confidence intervals around parameters, and/or falsify a-prior null-hypotheses, the Bayesian approach attempts to keep track of how a-prior expectations about some phenomenon of interest can be refined, and how observed data can be integrated with such a-prior beliefs, to arrive at updated posterior expectations about the phenomenon.
<b>Beta (<math>\beta</math>) Error</b>	In a test of a statistical hypothesis, the probability of failing to reject the null hypothesis when it is in fact false. Beta errors are also called type II errors, misses or false negatives.

<b>Bias</b>	Bias in a sample is the presence or influence of any factor that causes the population or process being sampled to appear different from what it actually is. Bias is introduced into a sample when data are collected without regard to key factors.
<b>Biomarker</b>	A characteristic (e.g., protein, gene) that is objectively measured and evaluated from a biological sample (e.g., tissue, blood) as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.
<b>Blinding</b>	A procedure in which one or more parties to the trial are kept unaware of the treatment assignment. Double (or triple) blinding means that investigators and/or health care providers, in addition to patients, are unaware of the treatment assignments.
<b>Clinical Endpoint</b>	An occurrence that measures the study hypothesis. It is often a characteristic or variable that reflects how a patient feels, functions, or survives, and used to measure whether a treatment is effective. <ul style="list-style-type: none"> <li>• Primary—what a trial is designed to assess</li> <li>• Secondary—other endpoints of interest</li> </ul>
<b>Clinical Trial</b>	A type of research study that assesses medical questions in people. These studies often test new methods of screening, prevention, diagnosis, or treatment of a disease.
<b>Comparison Group; Control Intervention or Control Treatment</b>	The treatment received by the comparison or control group, often a placebo. In cancer trials, the control intervention is usually the current standard of care.
<b>Confounding</b>	In research design, the problem that arises when two or more causal variables, often an independent variable and an extraneous variable, are not properly controlled, so that their separate effects on the outcome measure can not be disentangled.
<b>Comparison or Control Group or Arm</b>	A group of patients who are not treated with the experimental intervention (e.g., no therapy, a different therapy, or a placebo) This group is compared to the group that receives the experimental intervention, to see if the experimental intervention is effective.
<b>Correlation</b>	A statistical technique for determining the extent to which variations in the values of one variable are associated with variations in the value of another.



<b>Correlative Science</b>	A type of study that uses as its primary explanatory variables obtained from the laboratory, such as various genetic, proteomic, biomarker data extracted from tumors.
<b>Crossover</b>	Allowing patients who do not respond to the treatment to which they were randomly assigned, to switch to the alternative treatment after some pre-specified amount of time.
<b>Demographics</b>	Having to do with the structure of populations or population statistics (e.g., age, income, marital status).
<b>Dependent Variable</b>	A variable that is acted on or influenced by another variable. For example, in an investigation of the affect of drugs on cancer, the independent variable (e.g., drug type or dose) is manipulated and the affect of this manipulation can be seen in the change in the dependent variable or outcome (e.g., survival).
<b>Efficacy</b>	A drug's ability to produce beneficial effects on the course or duration of a disease. Efficacy can be measured in several ways, depending on the type of clinical trial.
<b>Eligibility Requirements</b>	Specifications of who may participate in a clinical trial. Eligibility requirements generally include details about the disease (e.g., organ site, stage), prior treatment, and co-morbidities.
<b>Endpoint</b>	In clinical trials, an event or outcome that can be measured objectively to determine whether the intervention being studied is beneficial. For example, a clinical trial studying a new cancer drug might use death as an endpoint to determine if people getting the drug lived longer than those who did not get the drug.
<b>Equivalence Trial</b>	A clinical trial designed to evaluate whether an experimental treatment is similar to a control treatment, by an appropriate definition of similarity. A two-sided (two-tailed) test of similarity is used.
<b>Evidence-Based Medicine</b>	Evidence-based medicine, defined by David Sackett, is 'the conscientious and judicious use of current best evidence from clinical care research, in the management of individual patients.'
<b>Experiment</b>	A scientific procedure undertaken to make a discovery, test a hypothesis, or demonstrate a known fact.

<b>Experimental Design</b>	The general plan of an experiment , including the method of assigning research participants or patients to treatment conditions , controlling extraneous variables , manipulating the independent variable , and measuring the dependent variable or outcome.
<b>Experimental or Investigational Group or Arm</b>	In clinical trials, a group of patients who receive the experimental or investigational intervention.
<b>Experimental or Investigational Intervention</b>	Term often used to denote a therapy (drug, drug dose or combination, device, or procedure) that is unproven or not yet scientifically validated with respect to safety and efficacy in humans.
<b>Frequentist or Traditional Statistics</b>	Traditional approach to statistical inference. Using hypothesis testing, it allows researchers to draw inferences about how likely they are to observe their data (or more extreme data) if the null hypothesis were true. Limits the relative frequency of drawing erroneous conclusions. It does not, however, allow researchers to assess the relative likelihood of competing hypotheses (other than the null hypothesis) in light of their data.
<b>Historical Controls</b>	Control group based on previous trials. Using historical controls is less costly in terms of time and money than including a randomized control group in a new trial. However, it typically introduces many unknown biases and is not generally acceptable for phase III trials.
<b>Hypothesis</b>	A tentative proposal made to explain certain observations or facts that require further investigation to be verified.
<b>Hypothesis Testing</b>	Hypothesis testing refers to the process of using statistical analysis to determine if the observed differences between two or more samples are due to random chance (as stated in the null hypothesis) or to true differences. A null hypothesis ( $H_0$ ) is a stated assumption that there is no difference in outcomes for two or more populations. The alternate hypothesis is a statement that the observed difference or relationship between two populations is real and not the result of chance or an error in sampling. Hypothesis testing is the process of using a variety of statistical tools to analyze data and, ultimately, to reject or not reject the null hypothesis.
<b>Incidence</b>	The frequency of occurrence or onset of new cases of a disorder as a proportion of a population in a specific time period, usually expressed as the number of new cases per 100,000 per annum.

<b>Independent Variable</b>	Variable that is manipulated, sometimes experimentally, in order to observe its effects on a dependent variable. For example, in an investigation of the affect of drugs on cancer, the independent variable (e.g., drug type or dose) is manipulated and the affect of this manipulation can be seen in the change in the dependent variable or outcome (e.g., survival). A variable that is acted on or influenced by another variable.
<b>Inductive Methods</b>	A form of reasoning, also called empirical induction, in which a general law or principle is inferred from particular instances that have been observed.
<b>Inference</b>	A conclusion reached on the basis of evidence and reasoning.
<b>Informed Consent</b>	A process in which a person is given important facts about a medical procedure or treatment, a clinical trial, or genetic testing before deciding whether or not to participate. It also includes informing the patient when there is new information that may affect his or her decision to continue. Informed consent includes information about the possible risks, benefits, and limits of the procedure, treatment, trial, or genetic testing.
<b>Institutional Review Board (IRB)</b>	An IRB is a committee with federal regulatory authority to review and approve research involving human subjects. An IRB is composed of a diverse group of men and women with expertise in science, ethics, and other non-scientific areas.
<b>Intent-to-Treat</b>	In reality, not all patients who enroll in a clinical trial complete the trial as planned. They may drop out, die, switch treatments, etc. How to deal with the data of such patients is problematic because the patients who drop out are often different from those who complete the trial. Thus, biostatisticians often conduct two analyses—one including all patients assigned to treatment arms (i.e., those intended-to-be-treated) and a second including only patients who actually were treated. When the results of these two analyses differ, it is likely that the intervention influenced the propensity of patients to drop out of the trial.
<b>Interaction</b>	The situation in which a treatment difference (e.g., difference between experimental and control) is dependent on another factor (e.g., study site, organ site, gender).

<b>Intervention</b>	The act or instance of intervening. In a clinical trial, an experimental or investigational intervention is compared to a comparison or control intervention. The interventions are often different treatment drugs, but may simple entail different schedules of drug administration, supportive therapies, etc.
<b>Investigational Treatment</b>	A new drug, biological drug, or combination that is used in a clinical investigation.
<b><i>In Vitro</i></b>	In the laboratory (outside the body). The opposite of <i>in vivo</i> (in the body).
<b><i>In Vivo</i></b>	In the body. The opposite of <i>in vitro</i> (outside the body or in the laboratory). Applies to both human and other animal bodies.
<b>Likelihood Ratio</b>	In Bayesian inference, the ratio between the probability of an observation or datum conditional on a hypothesis (numerator) and the probability of the same observation or datum conditional on an alternative hypothesis (denominator).
<b>Mean</b>	Measure of central tendency. Equally weighs all outcomes, and can be heavily influenced by outliers. Computationally, the mean is equal to the sum of outcomes, divided by the sample size.
<b>Median</b>	Measure of central tendency in which half of the outcomes are above and half below. The median is not affected by outliers.
<b>Meta-analysis</b>	The process of combining the data from a number of independent studies (usually drawn from published literature) and synthesizing summaries and conclusions addressing a particular issue. It aims to utilize the increased power of pooled data to clarify the state of knowledge on that issue. Meta analysis is often used in systematic reviews of studies of medical therapies to evaluate therapeutic effectiveness.
<b>Multi-Stage Trial Design</b>	Trials in which later stages of the trial are dependent up what happens in earlier stages. An example of a two-stage trial design is the randomized discontinuation design where a patient's treatment may be changed in the second stage of the trial, depending on the progress of the disease during the first stage.
<b>Non-inferiority Trial</b>	A clinical trial designed to evaluate whether an experimental treatment is similar to a control treatment, by an appropriate definition of similarity. A one-sided (one-tailed) test of similarity is used.

<b>Null Hypothesis (<math>H_0</math>)</b>	A null hypothesis ( $H_0$ ) is a stated assumption that there is no difference in outcomes for two or more populations. According to the null hypothesis, any observed difference in samples is due to chance or sampling error. The term that statisticians often use to indicate the statistical hypothesis being tested.
<b>One-Tail Test</b>	Test for deviation from the null hypothesis in only one direction. That is, the null hypothesis states that a specific group is superior to the other.
<b>Opportunity Costs</b>	The economic cost of an action measured in terms of the benefit foregone by not pursuing the best alternative course of action. In clinical research, opportunity costs are measured relative to alternative trials that could have been conducted on the same patient population, by the same researchers, and/or with the same funds.
<b>Outcome</b>	In clinical trials, an event or outcome that can be measured objectively to determine whether the intervention being studied is beneficial. In cancer clinical trials outcomes that are of common interest include overall survival time, disease-free survival time, five year survival rate, and proportion of patients' disease who respond to treatment.
<b>p Value</b>	The lowest level of significance at which a given null hypothesis can be rejected; that is, the probability of observing a result as extreme as or more extreme than that observed if the null hypothesis were true.
<b>Paradigm Shift</b>	A fundamental change in approach or underlying assumptions.
<b>Parameter</b>	A population parameter is the value of some quantitative characteristic in an entire population. It is estimated by a sample statistic.
<b>Patient Allocation Adaptive Design</b>	Adaptive design in which the proportion of patients assigned to each treatment arm is modified as data are accrued. Compared to traditional designs, these design generally come to conclusions faster and require fewer patients, and with a larger proportion of the patients receiving the superior treatment.
<b>Patient Enrichment</b>	In the context of clinical trials, patient enrichment entails restricting patient eligibility to those most likely to benefit from the experimental treatment. As cancer treatments become more targeted, patients who are most likely to benefit can be selected based on biomarkers in the tumor or circulating cells, proteins in the blood, or genetic factors that influence the way drugs are metabolized.

<b>Patient Preference Design</b>	Design in which patients decides whether or not to be randomized, or to select their own treatment. Compared to traditional designs, these designs generally accrue more rapidly and are more satisfactory to patients.
<b>Phase 0 Trial</b>	Phase 0 trials are a novel concept in clinical trials. They involve testing small, non therapeutic amounts of drug to obtain preliminary pharmacokinetic information, and assist pharmaceutical companies in decisions on pursuing further development of the agent. Pharmacokinetics is the study of the metabolism and action of drugs with particular emphasis on the time required for absorption, duration of action, distribution in the body, and method excretion.
<b>Phase I Trial</b>	The first step in testing a new treatment in humans. These studies test the best way to give a new treatment (for example, by mouth, intravenous infusion, or injection) and the highest tolerable dose. The dose is usually increased a little at a time in order to find the highest dose that does not cause harmful side effects. Because little is known about the possible risks and benefits of the treatments being tested, Phase I trials usually include only a small number of patients who have not been helped by other treatments without a comparison group.
<b>Phase II Trial</b>	A study to test whether an experimental intervention has an anticancer effect (for example, whether it shrinks a tumor or improves blood test results) and whether it works against a certain type of cancer.
<b>Phase III Trial</b>	A study to compare the results of people taking an experimental intervention with the results of people taking the standard of care (for example, which group has better survival rates or fewer side effects). In most cases, studies move into phase III only after an intervention seems to work in phases I and II. Phase III trials may include hundreds of people and always includes a control group.
<b>Phase IV Trial</b>	A study conducted after a treatment has been approved and is being marketed to evaluate side effects that were not apparent in the phase III trial. Thousands of people are involved in a phase IV trial.
<b>PICO</b>	The acronym PICO is used by health professionals to convey all elements of the clinical scenario in an orderly fashion: <b>P</b> - patient, population of patients, problem <b>I</b> - intervention (a therapy, test) <b>C</b> - comparison (another therapy, placebo) <b>O</b> - outcome (survival, response)

<b>Pivotal Trial</b>	A controlled trial to evaluate the safety and efficacy of a drug in patients who have the disease or condition to be treated.
<b>Placebo</b>	An inactive substance or treatment that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo.
<b>Population</b>	The entire collection of people (current and future) who are the focus of interest (e.g., all people with a specific type of cancer).
<b>Population Parameter</b>	A value of some quantitative characteristic in a population. Population parameters are estimated by sample statistics calculated from sample data (e.g., sample mean).
<b>Posterior Probability</b>	The posterior probability is the conditional probability of a variable, taking the evidence into account. The posterior probability is computed from the prior probability and the likelihood function via Bayes' theorem.
<b>Power</b>	Power is the probability of rejecting the null hypothesis if it is really false. It is mathematically equal to $1 - \beta$ and is dependent upon the sample size, sample variance, the effect size and type II error rate.
<b>Prevalence</b>	The total number of existing cases of a disorder as a proportion of a population (usually per 100,000 people) at a specific time.
<b>Primary Endpoint</b>	The main result that is measured to see if a given treatment worked (e.g., the number of deaths or the difference in survival between the treatment group and the control group). The primary endpoint is determined by the primary study objective, and is defined prior to the start of the trial.
<b>Prior Probability</b>	A prior probability is a base rate, interpreted as a description of what is known about a variable in the absence of some evidence.
<b>Probability</b>	The likelihood that a given event will occur. Probability is expressed as values between 0 (complete certainty that an event will not occur) to 1 (complete certainty that an event will occur), or percentage values between 0 and 100%.

<b>Protocol</b>	An action plan for a clinical trial. The plan states what the study will do, how, and why. It explains how many people will be in it, who is eligible to participate, what study agents or other interventions they will be given, what tests they will receive and how often, and what information will be gathered.
<b>Quality of Life (QOL)</b>	Measurement of aspects of an individual's sense of well-being and ability to perform various tasks.
<b>Randomization</b>	The process by which patients are assigned by chance to separate groups that compare different treatments or other interventions. Randomization can use equal weighting (i.e., 50:50) or not (e.g., 75:25)
<b>Randomized Controlled Trial</b>	A research design used for testing the effectiveness of a drug, or any other type of experimental intervention, in which research participants are assigned randomly to experimental and control or groups and the differences in outcomes are compared.
<b>Randomized Discontinuation Design</b>	Design in which all patients initially receive the experimental treatment. In a second stage of the trial a subgroup of patients is randomized. Compared to traditional designs, these designs generally provide better information about the sub-set of patients most likely to benefit from an experimental treatment and are often preferred by patients.
<b>Reliability</b>	Reliability is the extent to which an experiment, test, or any measuring procedure yields the same result on repeated trials. Without the agreement of independent observers able to replicate research procedures, or the ability to use research tools and procedures that yield consistent measurements, researchers would be unable to satisfactorily draw conclusions, formulate theories, or make claims about the generalizability of their research.
<b>Research Advocate</b>	Individuals or organizations who try to raise public awareness about important cancer issues, particularly those related to research. They work with researchers to ensure that research is patient focused and likely to result in changes in clinical practice.
<b>Sample</b>	A subset of a population selected to draw inferences about the population. It is a random sample if it is chosen in such a way that every sample of the same size has an equal chance of being selected.
<b>Sampling Distribution</b>	Every statistic is a random variable because its value varies from one sample to another. The distribution of this random variable is a sampling distribution.



<b>Scientific Method</b>	A method of procedure that has characterized natural science since the 17th century, consisting of systematic observation, measurement, and experiment, and the formulation, testing, and modification of hypotheses.
<b>Secondary Endpoints</b>	These are outcomes that are of interest in addition to the primary endpoints that a clinical trial is designed to assess. Examples include quality of life (QOL) measures and treatment side effects.
<b>Sensitivity</b>	The conditional probability of a test correctly giving a positive result, given that the patient does have the disease.
<b>Side Effect</b>	A problem that occurs when treatment affects healthy tissues or organs. Some common side effects of cancer treatment are fatigue, pain, nausea, vomiting, decreased blood cell counts, hair loss, and mouth sores. Serious side effects are often referred to as adverse events.
<b>Specificity</b>	The conditional probability of a test correctly giving a negative result, given that the patient does not have the disease.
<b>Standard of Care or Standard Treatment</b>	In medicine, treatment that experts agree is appropriate, accepted, and widely used. Health care providers are obligated to provide patients with the standard of care. Also called standard therapy or best practice.
<b>Standard Deviation</b>	Measure of dispersion calculated from samples and used to estimate population variances. Computationally, the standard deviation is equal to the square root of the variance.
<b>Statistic</b>	A statistic is the value of some quantitative characteristic in a sample taken to be an estimate of the equivalent population parameter.
<b>Statistics</b>	The scientific discipline concerned with the collection, analysis, interpretation, and presentation of data.
<b>Statistical Analysis</b>	Statistical analysis relates observed statistical data to theoretical models, such as probability distributions or models used in regression analysis. By estimating parameters in the proposed model and testing hypotheses about rival models, one can assess the value of the information collected and the extent to which the information can be applied to similar situations. Statistical prediction is the application of the model thought to be most appropriate, using the estimated values of the parameters.

<b>Statistical Inference</b>	Statistical inference involves the selection of one conclusion from a number of alternatives according to the result of a calculation based on observations.
<b>Statistical Significance</b>	A term indicating that the results of a study are stronger than would be expected by chance alone.
<b>Stratification</b>	The placing of the trial population into categories (i.e., strata) which are: 1) exhaustive (i.e., all strata together include the entire trial population); 2) mutually exclusive and; 3) related to the criteria being studied.
<b>Stratification Variable</b>	The variable which form the basis of stratification. Examples include gender or age, disease site or stage.
<b>Sub-Group Analysis</b>	Analyses that look for treatment difference in sub-groups of the experimental and control groups. For example, is there a treatment effect in males but not females or in one organ site but not another. If these analyses are planned prior to running the trial, statistical procedures can be used to limit a or type I errors, although at a cost to power. They can be especially problematic when they are not pre-planned.
<b>Superiority Trial</b>	A clinical trial designed to evaluate whether an experimental treatment is superior to a control treatment, by an appropriate definition of similarity. A one-sided test would be used.
<b>Supportive Therapy</b>	A treatment designed to improve, reinforce, or sustain a patient's physiological well-being or psychological self-esteem and self-reliance. In cancer trials, supportive therapies are typically given to prevent or minimize toxic side-effects of therapies used to treat the cancer.
<b>Surrogate Endpoint</b>	A biomarker that is intended to substitute for a clinical endpoint (e.g., survival). A surrogate endpoint is expected to predict clinical benefit (or harm or lack of benefit or harm) based on epidemiologic, therapeutic, pathophysiologic, or other scientific evidence.
<b>Test Statistic</b>	A statistic used in hypothesis testing. It has a known distribution if the null hypothesis is true.
<b>Treatment</b>	Any intervention—drug, surgery, psychosocial intervention—being investigated in a clinical trial.
<b>Treatment Arm</b>	Any of the treatment groups in a randomized trial. Many randomized trials have two arms—one experimental and one control—but some have three or more “arms,” and some have only one.

<b>Treatment Effect</b>	The treatment effect is the difference in outcomes between the group of patients who received the experimental or investigational treatment and those who received the comparison or control treatment.
<b>Treatment Protocol</b>	The treatment protocol specifies all details about the interventions that are to be given to both the experimental or investigational group and the comparison or control group. This includes drug dose and schedule, as well as test procedures and any other interventions that are part of the trial.
<b>Two Tail Test</b>	Testing for deviation from the null hypothesis in either direction.
<b>Type I Error</b>	In a test of a statistical hypothesis, the probability of rejecting the null hypothesis when it is true. Also called an alpha error or false positive.
<b>Type II Error</b>	In a test of a statistical hypothesis, the probability of failing to reject the null hypothesis when it is in fact false. Type II errors are also called beta errors, misses or false negatives.
<b>Underserved Patient Populations</b>	Populations whose participation in clinical trials is less than their representation in the overall population of people affected by a disease. Underserved populations typically include minorities, people of lower socio-economic background, the elderly, and people who live in rural areas.
<b>Validity</b>	Validity refers to the degree to which a study accurately reflects or assesses the specific concept that the researcher is attempting to measure. Researchers should be concerned with both external and internal validity. External validity refers to the extent to which the results of a study are generalizable or transferable. Internal validity refers to: 1) the rigor with which the study was conducted (e.g., the study's design, the care taken to conduct measurements, and decisions concerning what was and wasn't measured); and 2) the extent to which the designers of a study have taken into account alternative explanations for any causal relationships they explore.
<b>Variable</b>	The characteristic measured or observed when an experiment is carried out or an observation is made. Variables may be non-numerical or numerical. Since a non-numerical observation can always be coded numerically, a variable is usually taken to be numerical. Statistics is concerned with random variables and with variables whose measurement may involve random errors

**Variability**

The degree to which a set of outcomes is dispersed or scattered. Two sets of outcomes with identical means (averages) may have widely different variances. The usual measures of variability are the variance and standard deviation.

**Variance**

Measure of dispersion calculated in samples and used to estimate population variances. Computationally, the variance is equal to the average squared deviation from the mean.

## Glossary Sources

<http://www.cancer.gov/dictionary/>

<http://www.cancer.gov/statistics/glossary>

<http://www.cancer.gov/prevention/CTR/glossary.html>

<http://www.fda.gov/cder/drugsatfda/glossary.htm>

<http://www.nlm.nih.gov/medlineplus/mplusdictionary.htm>

<http://www.med.umich.edu/cacr/dictionary/A-B.htm>

<http://www.oxfordreference.com.proxy.lib.umich.edu/views/GLOBAL.html>

<http://www.isixsigma.com/dictionary/>

<http://writing.colostate.edu/guides/research/relval/>